(3R,4S)-4-[[2-(5-氟-2-羟基苯基)-6,7-二甲氧基-4-喹唑啉基]氨基]-ALPHA,ALPHA-二甲基-3-吡咯烷甲醇
中文名称 | (3R,4S)-4-[[2-(5-氟-2-羟基苯基)-6,7-二甲氧基-4-喹唑啉基]氨基]-ALPHA,ALPHA-二甲基-3-吡咯烷甲醇 |
---|---|
中文同义词 | (3R,4S)-4-[[2-(5-氟-2-羟基苯基)-6,7-二甲氧基-4-喹唑啉基]氨基]-ALPHA,ALPHA-二甲基-3-吡咯烷甲醇;化合物 T10718;化合物 CCT241533 |
英文名称 | CCT241533 |
英文同义词 | (3R,4S)-4-[[2-(5-Fluoro-2-hydroxyphenyl)-6,7-dimethoxy-4-quinazolinyl]amino]-alpha,alpha-dimethyl-3-pyrrolidinemethanol;CCT241533;CCT241533 (CCT 241533;CS-198;3-Pyrrolidinemethanol, 4-[[2-(5-fluoro-2-hydroxyphenyl)-6,7-dimethoxy-4-quinazolinyl]amino]-α,α-dimethyl-, (3R,4S)-;4-Fluoro-2-(4-(((3S,4R)-4-(2-hydroxypropan-2-yl)pyrrolidin-3-yl)amino)-6,7-dimethoxyquinazolin-2-yl)phenol |
CAS号 | 1262849-73-9 |
分子式 | C23H27FN4O4 |
分子量 | 442.4832832 |
EINECS号 | 200-258-5 |
相关类别 | 细胞周期;对照品 |
Mol文件 | 1262849-73-9.mol |
结构式 |
(3R,4S)-4-[[2-(5-氟-2-羟基苯基)-6,7-二甲氧基-4-喹唑啉基]氨基]-ALPHA,ALPHA-二甲基-3-吡咯烷甲醇 性质
沸点 | 569.4±50.0 °C(Predicted) |
---|---|
密度 | 1.327 |
储存条件 | Store at -20°C |
溶解度 | 溶于二甲基亚砜 |
形态 | 结晶固体 |
酸度系数(pKa) | 8.18±0.48(Predicted) |
颜色 | 白色至米白色 |
Chk2 3 nM (IC 50 ) |
Chk1 245 nM (IC 50 ) |
Chk2 1.16 nM (Ki) |
CCT241533 hydrochloride inhibits CHK2 with an IC 50 of 3 nM and shows minimal cross reactivity against a panel of kinases at 1 μM. X-ray crystallography confirms that CCT241533 binds to CHK2 in the ATP pocket. CCT241533 blocks CHK2 activity in human tumor cell lines in response to DNA damage, as demonstrated by inhibition of CHK2 autophosphorylation at S516, band-shift mobility changes and HDMX degradation. CCT241533 does not potentiate the cytotoxicity of a selection of genotoxic agents in several cell lines. However, CCT241533 significantly potentiates the cytotoxicity of two structurally distinct PARP inhibitors. Clear induction of the pS516 CHK2 signal is seen with a PARP inhibitor alone and this activation is abolished by CCT241533. The cytotoxicity of CCT241533 in HT-29, HeLa and MCF-7, measured as the growth inhibitory IC 50 (GI 50 ) by SRB assay, is 1.7, 2.2 and 5.1 μM, respectively. CCT241533 hydrochloride is a potent CHK2 inhibitor (IC 50 =3 nM), with selectivity (63-fold) over CHK1(IC 50 =190 nM) and low hERG inhibition (IC 50 =22 μM).